扩大供者选择:单倍体相合移植受者也很可能拥有7/8相合无关供者
研究分析了2013至2020年间美国9696例接受单倍体相合亲缘供者(HRD)造血细胞移植并报告至国际血液与骨髓移植研究中心的患者,利用美国国家骨髓捐献者计划(NMDP)登记处的检索预后评分和检索模拟评估无关供者(URD)的存在情况。结果显示34%的受者有至少1个8/8相合URD,84%有至少1个7/8相合URD;NMDP检索预后评分因患者祖源而异。结论认为大多数接受HRD移植的美国患者没有现存的8/8相合URD,但多数有现存的7/8相合URD,可能需要开展比较HRD与7/8相合URD移植联合基于移植后环磷酰胺(PTCy)的移植物抗宿主病预防的结局研究。
要点
- 9696例HRD移植受者中,34%有至少1个8/8相合URD,84%有至少1个7/8相合URD。
- NMDP检索预后评分良好者中,非西班牙裔白人占27.5%,非裔美国人占4.6%。
- HRD年龄≥35岁的受者拥有至少5个年龄≤35岁的现存7/8相合URD的可能性在20%至65%之间。
核心结论
- 大多数接受HRD移植的美国患者没有现存的8/8相合URD,但多数有现存的7/8相合URD。
- 可能需要开展比较接受HRD或7/8相合URD移植联合基于PTCy的移植物抗宿主病预防的患者结局的研究。
研究设计与样本
- 研究分析了2013年至2020年间在美国接受HRD造血细胞移植并报告至国际血液与骨髓移植研究中心的9696例HRD移植受者。
- 使用NMDP检索预后评分和检索模拟来估计登记处URD相合的数量。
主要发现
- NMDP检索预后评分因患者祖源而异,27.5%的非西班牙裔白人有良好评分,而非洲裔美国人HRD移植受者中该比例为4.6%。
- 总体而言,34%的受者有至少1个8/8相合URD,84%有至少1个7/8相合URD。
- HRD年龄≥35岁的受者拥有至少5个年龄≤35岁的现存7/8相合URD的可能性在20%至65%之间。
- 在10个HRD移植量最高的中心中,供者选择实践存在差异:6个中心其HRD受者存在8/8相合URD的可能性>20%,而4个中心识别8/8相合URD的可能性低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The use of haploidentical related donor (HRD) hematopoietic cell transplants (HCTs) in the United States grew by more than fourfold in the last decade, driven mainly by use of posttransplant cyclophosphamide (PTCy)-based graft-versus-host-disease prophylaxis. However, not all patients have a suitable HRD available. In this study, we explored the existence of unrelated donors (URDs) on the National Marrow Donor Program (NMDP) registry at the 8/8- or 7/8-match level for patients receiving HRD HCT in the United States and reporting to the Center for International Blood and Marrow Transplant Research between 2013 and 2020. The data consist of 9696 HRD HCT recipients. The NMDP search prognosis score and a search simulation were used to estimate counts of URD matches on the registry. NMDP search prognosis varied by patient ancestry, with 27.5% non-Hispanic White having a good score compared with 4.6% of African American HRD HCT recipients. Overall, 34% of recipients had ≥1 8/8-matched URDs and 84% had ≥1 7/8 URDs. Recipients of older HRDs (≥35 years) had a likelihood of between 20%- 65% of having ≥5 existing 7/8-matched URDs who were aged ≤35 years. Donor-selection practices varied among the 10 highest-volume HRD centers: 6 had >20% chance of an existing 8/8-matched URD for their HRD recipients, whereas 4 centers had low likelihood of identifying an 8/8-matched URD. In conclusion, although most US patients undergoing HRD HCT do not have an existing 8/8 URD, the majority have an existing 7/8-matched URD. Studies comparing outcomes in patients receiving either HRD or 7/8-matched URD HCT and PTCy-based graft-versus-host disease prophylaxis may be warranted.
引用
- Fingerson S, Maiers M, Bolon YT, et al. Expanding donor options: haploidentical transplant recipients are also highly likely to have a 7/8-matched unrelated donor. Blood Adv. 2024. PMID: 38127270. doi:10.1182/bloodadvances.2023011814
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。